The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Tech-driven calculator, which serves as a preventive tool that helps in heart risk assessment using several factors
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Subscribe To Our Newsletter & Stay Updated
